These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25403214)

  • 1. Reply to H.L. McArthur et al.
    Vaz-Luis I; Lin NU
    J Clin Oncol; 2015 Jan; 33(1):125. PubMed ID: 25403214
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    McArthur HL; Morris PG; Hudis CA
    J Clin Oncol; 2015 Jan; 33(1):124-5. PubMed ID: 25403210
    [No Abstract]   [Full Text] [Related]  

  • 3. How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers.
    Reeder-Hayes KE; Carey LA
    J Clin Oncol; 2014 Jul; 32(20):2122-4. PubMed ID: 24888811
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to L. Cabel et al.
    Fehrenbacher L; Capra A; Habel L
    J Clin Oncol; 2015 Jan; 33(3):292-3. PubMed ID: 25512452
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognosis of t1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas.
    Cabel L; Péron J; Cottu PH; Rodrigues MJ
    J Clin Oncol; 2015 Jan; 33(3):291. PubMed ID: 25512462
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to P.G. Gavin et al.
    Perez EA; Thompson EA; Ballman KV
    J Clin Oncol; 2015 Nov; 33(31):3672-3. PubMed ID: 26282664
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
    Wolff AC; Hammond ME; Hayes DF
    J Natl Cancer Inst; 2012 Jun; 104(12):957-8. PubMed ID: 22581974
    [No Abstract]   [Full Text] [Related]  

  • 8. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
    Fehrenbacher L; Capra AM; Quesenberry CP; Fulton R; Shiraz P; Habel LA
    J Clin Oncol; 2014 Jul; 32(20):2151-8. PubMed ID: 24888815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HER2-positive breast cancer: standard and double targeted therapy].
    Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
    Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls.
    Gavin PG; Song N; Kim SR; Pogue-Geile KL; Paik S
    J Clin Oncol; 2015 Nov; 33(31):3671-2. PubMed ID: 26282639
    [No Abstract]   [Full Text] [Related]  

  • 11. Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.
    Prat A; Baselga J
    J Clin Oncol; 2013 May; 31(14):1703-6. PubMed ID: 23569319
    [No Abstract]   [Full Text] [Related]  

  • 12. Are immune signatures a worthwhile tool for decision making in early-stage human epidermal growth factor receptor 2-positive breast cancer?
    Foekens JA; Martens JW; Sleijfer S
    J Clin Oncol; 2015 Mar; 33(7):673-5. PubMed ID: 25605833
    [No Abstract]   [Full Text] [Related]  

  • 13. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply to a. Avan et Al.
    Baselga J; Clark E; Kiermaier A; Swain SM
    J Clin Oncol; 2015 May; 33(15):1712. PubMed ID: 25870094
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment combinations for HER2-positive breast cancer.
    Pegram M
    Oncology (Williston Park); 2013 Apr; 27(4):258, 260. PubMed ID: 23781688
    [No Abstract]   [Full Text] [Related]  

  • 16. Bevacizumab for advanced breast cancer: all tied up with a RIBBON?
    Burstein HJ
    J Clin Oncol; 2011 Apr; 29(10):1232-5. PubMed ID: 21383305
    [No Abstract]   [Full Text] [Related]  

  • 17. Weighing the options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer.
    Lin NU
    J Clin Oncol; 2015 May; 33(14):1530-3. PubMed ID: 25847924
    [No Abstract]   [Full Text] [Related]  

  • 18. POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
    Goel S; Winer EP
    Oncology (Williston Park); 2015 Nov; 29(11):797-8, 802. PubMed ID: 26573058
    [No Abstract]   [Full Text] [Related]  

  • 19. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.
    Ellis MJ
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535
    [No Abstract]   [Full Text] [Related]  

  • 20. [Modern pharmacological therapy of breast cancer].
    Láng I; Kahán Z; Hitre E; Dank M; Rubovszky G; Horváth Z; Kásler M
    Orv Hetil; 2012 Jan; 153(2):56-65. PubMed ID: 22217685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.